Neurothera Labs Inc., a clinical-stage biotech company, has entered into a definitive agreement to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQuantum Ltd., a quantum technology company focused on applying quantum simulation to clinical trials. The transaction, valued at approximately $9.46 million based on Neurothera's share price, involves issuing 56.6 million common shares to CliniQuantum's selling shareholders and includes potential earn-out payments of up to US$2.5 million contingent on milestone achievements.
The acquisition represents a strategic move to integrate quantum computing capabilities into pharmaceutical research and development. CliniQuantum is developing a next-generation platform designed to transform clinical trials by using quantum computing to analyze massive, complex datasets, potentially enabling smarter, faster, and more adaptive study designs. This integration could significantly accelerate drug development timelines and improve trial efficiency in an industry where traditional clinical studies are often lengthy and costly.
Under the share purchase agreement dated March 9, 2026, Neurothera will acquire 56,375 CliniQuantum shares from certain shareholders. In addition to the consideration shares, selling shareholders may receive earn-out payments contingent on specific milestones: US$500,000 for each of the first three patent applications filed by CliniQuantum with the United States Patent and Trademark Office or the European Patent Office, up to US$1.5 million total, plus 7.0% of any fundraising proceeds raised by Neurothera, up to US$1 million. These payments are payable during the three-year period following the transaction's closing.
The transaction requires approval from the TSX Venture Exchange and is expected to close within 30 days following submission of an application for an Israeli tax ruling. All shares issued in connection with the transaction will be subject to a statutory hold period of four months plus one day. The company will also issue 2,829,999 finder's shares to certain arm's length finders. Forward-looking statements in the announcement caution that actual results may differ due to various risks and uncertainties, including the successful completion of the transaction and obtaining required regulatory approvals. Additional information about these risks is available in the company's public filings on SEDAR+.
This acquisition matters because it represents one of the first major integrations of quantum computing technology specifically into the clinical trial process. The pharmaceutical industry faces persistent challenges with trial design, patient recruitment, and data analysis that can delay life-saving treatments. Quantum computing's ability to process complex datasets could revolutionize how trials are designed and analyzed, potentially reducing development costs and bringing treatments to market faster. For patients awaiting new therapies, this technology could mean accelerated access to innovative treatments. The transaction also signals growing recognition within biotech that emerging technologies like quantum computing may provide competitive advantages in drug development.
